These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26119487)

  • 1. The global challenge of new classes of antibacterial agents: an industry perspective.
    Fernandes P
    Curr Opin Pharmacol; 2015 Oct; 24():7-11. PubMed ID: 26119487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of antibacterial discovery revisited.
    Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
    Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR;
    J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic bill doesn't GAIN enough ground.
    Ambrose PG
    Nat Med; 2011 Jul; 17(7):772. PubMed ID: 21738147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of antibiotics.
    Spellberg B
    Crit Care; 2014 Jun; 18(3):228. PubMed ID: 25043962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.
    Bhatti T; Lum K; Holland S; Sassman S; Findlay D; Outterson K
    J Law Med Ethics; 2018 Jun; 46(1_suppl):59-65. PubMed ID: 30146959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections.
    Singer AC; Kirchhelle C; Roberts AP
    F1000Res; 2019; 8():238. PubMed ID: 30906539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery research: the scientific challenge of finding new antibiotics.
    Livermore DM;
    J Antimicrob Chemother; 2011 Sep; 66(9):1941-4. PubMed ID: 21700626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forging a new path. New law offers incentives to develop antibiotics.
    Lee J
    Mod Healthc; 2013 Feb; 43(5):8-9. PubMed ID: 23437480
    [No Abstract]   [Full Text] [Related]  

  • 20. Small steps to new drugs for bugs.
    Melander RJ; Selwood DL
    Chem Biol Drug Des; 2015 Jan; 85(1):1-3. PubMed ID: 25521640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.